DIMENHYDRINATE INJECTION USP 50 MG
DIMENHYDRINATE : 50 MG · DIN 02536536 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is DIMENHYDRINATE INJECTION USP?
DIMENHYDRINATE INJECTION USP 50 MG contains DIMENHYDRINATE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02536536, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 27-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIMENHYDRINATE INJECTION USP used for?
Dimenhydrinate Injection USP and Sandoz Dimenhydrinate are indicated for use in the prevention and relief of nausea, vomiting and/or vertigo. These symptoms may be associated with clinical situations such as motion sickness, radiation sickness, postoperative recovery, drug-induced nausea and vomiting, Ménière's disease and other labyrinthine disturbances.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02536536 |
|---|---|
| Brand name | DIMENHYDRINATE INJECTION USP |
| Generic / active ingredient | DIMENHYDRINATE : 50 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Ethical |
| ATC code | R06AA11 DIMENHYDRINATE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Aug-2024 |
How is it stored and handled?
Sandoz Dimenhydrinate (suppositories) below 25°C. Dimenhydrinate Injection USP: controlled room temperature (15-30°C). Protect from freezing. Protect from light.
How is it supplied?
Dimenhydrinate Injection USP 50 mg/mL: ampoules of 1 mL, boxes of 10 ampoules; multidose vials of 5 mL, boxes of 10. Dimenhydrinate Injection USP 10 mg/mL: single use vials of 5 mL, boxes of 10. Sandoz Dimenhydrinate Suppositories 50 mg: Boxes of 10. Sandoz Dimenhydrinate Suppositories 100 mg: Boxes of 10.
Is DIMENHYDRINATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R06AA11 DIMENHYDRINATE. 20 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANTI-NAUSEANT | 50 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02241532 |
| ANTI-NAUSEANT LIQUID GELS | 50 MG | CAPSULE | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02493004 |
| CONFAB DIMENHYDRINATE 100 MG | 100 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392545 |
| CONFAB DIMENHYDRINATE 50 MG | 50 MG | SUPPOSITORY | LABORATOIRES CONFAB INC | MARKETED | DIN 00392553 |
| DIMENHYDRINATE INJECTION USP | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392731 |
| DIMENHYDRINATE INJECTION USP | 250 MG / 5 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02435241 |
| DIMENHYDRINATE INJECTION USP | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00392537 |
| DIMENHYDRINATE INJECTION USP | 50 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02428954 |
| GAVISCON NAUSEA | 50 MG | TABLET | MEDTECH PRODUCTS INC | MARKETED | DIN 02490528 |
| GRAVOL CHEWABLES | 50 MG | TABLET (CHEWABLE) | CHURCH & DWIGHT CANADA CORP | MARKETED | DIN 02384132 |
Who else supplies DIMENHYDRINATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIMENHYDRINATE appears in 8 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.